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Objective To compare electrodiathermy with helium thermal
coagulation in laparoscopic treatment of mild-to-moderate
endometriosis.
Design Parallel-group randomised controlled trial.
Setting A UK endometriosis centre.
Population Non-pregnant women aged 16–50 years with a clinical
diagnosis of mild-to-moderate endometriosis.
Methods If mild or moderate endometriosis was confirmed at
laparoscopy, women were randomised to laparoscopic treatment
with electrodiathermy or helium thermal coagulator.
Main outcome measures Cyclical pain and dyspareunia (rated on
a 100-mm visual analogue scale, VAS), quality of life at baseline
and at 6, 12 and 36 weeks following surgery, operative blood loss
and surgical complications.
Results A total of 192 women were randomised. Of these, 155
(81%) completed the primary outcome point at 12 weeks. In an
intention-to-treat analysis, VAS scores for cyclical pain were
significantly lower in the electrodiathermy group compared with
the helium group at 12 weeks (mean difference, 9.43 mm; 95% CI
0.46, 18.40 mm; P = 0.039) and across all time points (mean
difference, 10.13 mm; 95% CI 3.48, 16.78 mm; P = 0.003). A
significant difference in dyspareunia also favoured
electrodiathermy at 12 weeks (mean difference, 11.66 mm;
95% CI 1.39, 21.93 mm; P = 0.026). These effects were smaller
than the proposed minimum important difference of 18.00 mm,
however. Differences in some aspects of quality of life favoured
electrodiathermy. There was no significant difference in operative
blood loss (fold-change with helium as reference, 1.43; 95% CI
0.96, 2.15; P = 0.081).
Conclusions Although electrodiathermy was statistically superior
to helium ablation in reducing cyclical pain and dyspareunia,
these effects may be too small to be clinically significant.
Keywords Endometriosis, laparoscopic surgery, pelvic pain.
Tweetable abstract Helium coagulation is not superior to
electrodiathermy in laparoscopic treatment of mild-to-moderate
endometriosis.
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Introduction
Endometriosis is described as the presence of endometrium
or endometrium-like tissue at sites other than the uterine
cavity.1 This chronic and benign gynaecological condition
has a prevalence of approximately 5–10% in women of
reproductive age, increasing to 30–50% in cases of infertil-
ity.1,2 Prevalence peaks between 25 and 35 years of age.1
Symptoms include abdominopelvic pain, dyspareunia and
infertility,3 all of which can decrease quality of life.4
Endometriosis is challenging to treat owing to the
chronic and recurrent nature of the symptoms, the severityTrial registration: ISRCTN 50928834.
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Randomised Controlled Trial
of which does not correlate with the extent of disease visu-
alised at laparoscopy, which is the gold standard for diag-
nosis.3 There is frequently a significant delay from the
onset of symptoms to final diagnosis, leading to further
morbidity.5 The problem is compounded by a lack of
objectivity in assessing clinical features, relying upon the
subjective perception of pain severity, which shows
interindividual variation.
Treatment aims for endometriosis include relieving pain
and improving fertility. Analgesia, with or without hor-
monal therapies, may be used on an empirical basis before
a formal diagnosis is made.6 If symptoms persist despite
medical treatment, a ‘see-and-treat’ approach may be
undertaken whereby endometriosis is treated with excision
and/or ablation at the initial diagnostic laparoscopy.6
A meta-analysis has demonstrated that laparoscopic sur-
gery can improve symptoms of endometriosis.7 Typically,
endometriosis is treated with electrodiathermy; however,
there are limitations as to where electrodiathermy can be
safely used, for example when close to the bowel or the
bladder. An alternative procedure, the helium thermal coag-
ulator, uses a combination of helium gas and very low elec-
trical power (2–8 W) to deliver an inert plasma of gas to
the affected tissue. The probe is directed laparoscopically to
the affected area and has no physical contact with the tissue
when activated. Careful control of power levels allows extre-
mely precise degrees of cauterisation to be applied. Because
the interaction between electrons and tissue occurs in
helium, no smoke is generated. The low thermal spread
potentially allows for the safe ablation of endometriosis over
usually inoperable areas that could be injured with the
increased penetration of electrodiathermy, such as tissue
overlying the bladder, bowel and diaphragm. The National
Institute for Health and Care Excellence (NICE) cites evi-
dence relating to the safety of the technique from case series
but recognises a lack of evidence relating to efficacy.8
The objective of this study was to determine whether
laparoscopic treatment of mild-to-moderate endometriosis
with a helium thermal coagulator is associated with supe-
rior symptom relief and reduced morbidity, compared with
treatment using electrodiathermy.
Methods
We conducted a randomised parallel-group controlled trial,
with equal allocation, in which patients with mild-to-mod-
erate endometriosis underwent laparoscopic excision and/
or ablation of endometriosis with either helium thermal
coagulator or hook electrodiathermy.
Participants and recruitment
Women between the ages of 16 and 50 years presenting
with pelvic pain and a clinical diagnosis of mild or
moderate endometriosis, between January 2014 and
September 2017, in a UK gynaecology outpatient clinic,
were offered recruitment into the trial following a full
explanation. We excluded women with possible gynaeco-
logical cancer, women with advanced endometriosis and
women who were currently pregnant. The patient then gave
written consent and baseline data on outcome measures
were recorded prior to surgery. A translator was provided
where necessary.
Sample size
To detect a 12-week mean difference in visual analogue
scale (VAS) scores for cyclical pain of 18 mm with a stan-
dard deviation (SD) of 40 mm (assuming equal allocation,
80% power and a 5% two-tailed significance level), data
from a minimum of 79 women in each arm were required.
Assuming a maximum of 15% loss to follow up, at least 93
women needed to be recruited to each arm. The SD was
set at the highest relevant estimate found in the litera-
ture,9–12 and 18 mm was taken as the minimum important
between-group difference (MID), based on information
from this literature.11
Randomisation
Participants were randomised to laparoscopic ablation and/
or excision with either helium thermal coagulator or elec-
trodiathermy. A randomisation list, using random per-
muted blocks of sizes between 2 and 8, was drawn up by
an independent statistician and incorporated in a pass-
word-protected database constructed by an information
technology specialist who had no other role in the study.
Blinding
The study was double-blinded, whereby participants, asses-
sors and the trial statistician were not aware of the inter-
vention received. Of necessity, the surgeon was not blind to
the intervention. As both groups of patients had laparo-
scopic treatment, there were no indicators to the patients,
nursing staff or other clinicians to suggest which interven-
tion had been performed. Postoperative management did
not indicate to the women the procedure received, and
steps were taken to ensure that this was not revealed by
their treating surgeon during postoperative recovery, prior
to discharge (approximately 4 hours). An emergency
unblinding procedure was in place in the event of readmis-
sion with significant postoperative complications.
Procedure
Laparoscopy was performed to either confirm or exclude
the diagnosis of endometriosis. If endometriosis was pre-
sent, staging was performed using the Revised American
Society for Reproductive Medicine (RASRM) classification
of endometriosis.13 If no endometriosis was present, or the
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extent of the disease was greater than mild to moderate,
the patient was not randomised and was excluded from the
trial. In cases where endometriosis was confirmed, the sur-
geon then logged into the randomisation database and was
provided with the code for the procedure to be performed
(helium thermal coagulator or hook electrodiathermy). In
relation to both procedures, the surgeon performed abla-
tion and/or excision, depending upon clinical judgment as
to the severity and depth of the disease, and with regard to
delicate underlying structures. Intraoperative blood loss
and any complications were recorded. The patient was dis-
charged home after approximately 4 hours.
Data collection and outcome measures
Although recently published,14 no core outcome set for
endometriosis was available when the trial was designed to
guide the selection of outcome measures. Baseline data on
demographics, clinical history and outcome measures were
collected prior to surgery. The primary outcome measure
was cyclical pain. Secondary outcome measures were dys-
pareunia, quality of life, operative duration, intraoperative
blood loss, intraoperative visceral complications, postopera-
tive complications, and conception rates among those seek-
ing to become pregnant.
Participants were invited to attend a dedicated outpatient
follow-up clinic to be assessed by an independent practi-
tioner (research nurse), blind to the procedure that the
patient had received. Clinics were conducted at 6, 12 and
36 weeks following surgery. At each visit an assessment of
the worst intensity for both cyclical pain and dyspareunia
over the previous 4 weeks was performed using a 100-mm
VAS, commonly used for endometriosis-related symp-
toms.1,9,10,12,15,16 Quality of life was also assessed at these
time points using the Endometriosis Health Profile (EHP-
30) questionnaire.17,18 This measure has five 0–100 sub-
scales: pain, control and powerlessness, emotional wellbe-
ing, social support, and self-image. Lower scores indicate a
better quality of life.
Postoperative complications were assessed at the 6- and
12-week time points. Any participant who successfully con-
ceived, or attempted to do so, during the 36-week follow
up was also noted. Women failing to attend follow up were
sent a self-assessment form on the primary outcome (cycli-
cal pain intensity at 12 weeks) and asked to return this by
post.
Statistical analysis
Data analysis was blind to group allocation on an inten-
tion-to-treat basis. The primary outcome, between-group
differences in VAS scores for cyclical pain, was analysed at
12 weeks and also across the full follow-up period, with a
linear mixed model (with repeated observations clustered
within participants). Using maximum-likelihood
estimation, and assuming that values are missing at ran-
dom, this analysis accommodates missing data and thus
includes all randomised participants.19 Covariates in the
model, selected a priori, were baseline VAS scores, age, sur-
geon (surgeon A or surgeon B), staging on the RASRM
classification (mild, moderate or severe) and history of pre-
vious pelvic surgery (yes or no). For secondary outcomes, a
similar analysis was performed. Pregnancy rates were com-
pared using logistic regression, with maximum-likelihood
estimation. A secondary unadjusted analysis was performed
on the primary outcome measure, but an intended per-
protocol sensitivity analysis was not performed, as all but
one participant received the randomised intervention.20
Statistical significance was set at P ≤ 0.05 (two-tailed) and
95% confidence intervals (95% CIs) were calculated for all
estimates. The assumptions of all statistical models were
checked, and data were analysed with SPSS 25 (IBM,
Armonk, NY, USA).
Patient involvement
We held a focus group of patients prior to the study to
explore the perceived importance of the research, the proce-
dures to be tested, the choice of outcome measures and the
timing of their administration. The views expressed in the
focus group informed the design of these aspects of the
Table 1. Baseline characteristics (n = 192)
Diathermy
(n = 96)
Helium
(n = 96)
Age (years) 28.99 (6.99) 29.03 (7.11)
VAS score for cyclical pain (mm)* 76.52 (19.65) 72.14 (20.68)
VAS score for dyspareunia (mm)** 62.79 (30.49) 66.49 (27.53)
EHP-30 pain 59.00 (20.04) 56.46 (19.74)
EHP30 control and powerlessness 71.35 (22.95) 69.03 (22.93)
EHP-30 emotional wellbeing 55.86 (21.33) 56.79 (22.30)
EHP-30 social support 61.65 (25.11) 57.68 (27.48)
EHP-30 self-image 59.72 (27.30) 57.60 (30.85)
Surgeon: n (%) A 64 (66.7) 72 (75.0)
B 32 (33.3) 24 (25.0)
RASRM grade: n (%)*** 1 39 (41.5) 37 (41.6)
2 49 (52.1) 50 (56.2)
3 6 (6.4) 2 (2.2)
Previous laparotomy or
laparoscopy: n (%)****
Yes 46 (48.9) 42 (46.7)
No 48 (51.1) 48 (53.3)
Values are means (standard deviations), unless otherwise indicated.
EHP-30, Endometriosis Health Profile (each dimension scored 0–100;
lower scores indicate better quality of life); RASRM grade, Revised
American Society for Reproductive Medicine endometriosis
classification; VAS, visual analogue scale.
*Four missing values, n1 = 93, n2 = 95.
**Six missing values, n1 = 92, n2 = 94.
***Nine missing values, n1 = 94, n2 = 89.
****Eight missing values, n1 = 94, n2 = 90.
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study. Two patient representatives were co-applicants on the
funding proposal and subsequently became members of the
trial steering committee, and these and one other patient
representative reviewed the paper prior to submission.
Funding
This study was funded by the National Institute for Health
Research under its Research for Patient Benefit Programme
(project number PB-PG-0212-27072).
Results
One hundred and ninety-two women were randomised to
the two interventions between January 2014 and Septem-
ber 2017. In total, 274 women were excluded from the
study, 106 of whom were rejected once in theatre, pre-
dominantly because no endometriosis was identified at
laparoscopy. Baseline characteristics of randomised partici-
pants are shown in Table 1; variables were well balanced
across the trial arms. Progress through the trial is shown
in the Consolidated Standards of Reporting Trials (CON-
SORT) diagram (Figure 1). There was one protocol devia-
tion: a woman randomised to treatment with
electrodiathermy received treatment with a helium thermal
coagulator.
Among participants treated with helium thermal coagu-
lator, ablation was performed on 36 women (40%) and
excision was performed on seven women (8%); 47 women
(52%) received both ablation and excision. The corre-
sponding figures for electrodiathermy were one (1%), 20
(21%) and 73 (78%). Information was missing for eight
participants.
Table 2 shows the values of outcome variables at follow
up. For the primary outcome of cyclical pain, at the 12-
week follow up the covariate-adjusted VAS scores were sig-
nificantly lower in the electrodiathermy group compared
with the helium group (adjusted mean difference,
9.43 mm; 95% CI 0.46, 18.40 mm; P = 0.039). Across all
time points, there was also a significant difference in cycli-
cal pain favouring the electrodiathermy group (adjusted
mean difference, 10.13 mm; 95% CI 3.48, 16.78;
P = 0.003). Crucially, neither of these effects attained the
prespecified MID of 18.00 mm.
There was a significant difference at 12 weeks in dyspare-
unia in favour of the electrodiathermy group, although of
smaller magnitude than the MID (adjusted mean differ-
ence, 11.66 mm; 95% CI 1.39, 21.93 mm; P = 0.026), but
differences in other secondary outcomes at 12 weeks were
nonsignificant (Table 3). Profile plots for cyclical pain and
dyspareunia (adjusted mean values) are shown in Figure 2,
Parcipants assessed for 
eligibility
(n = 466)
Excluded (n = 274)
Ineligible n = 88
Unable/unwilling to consent n = 16
Missed in theatre/no paent 
informaon n = 32
Rejected in theatre n = 106
Other reasons n = 32
Randomized (n = 192)
Allocated to diathermy (n = 96)
Received diathermy n = 95
Received helium n = 1
No intervenon n = 0
Allocated to helium(n = 96)
Received helium n = 96
Received diathermy n = 0
No intervenon n = 0
Analysed on primary outcome at 12 weeks
(n = 80)
Lost to follow-up n = 16
Analysed on primary outcome at 12 weeks
(n = 75)
Lost to follow up n = 21
Figure 1. HYPERLINK "sps:id::fig1||locator::gr1" CONSORT diagram.
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showing a somewhat greater difference towards the end of
the follow-up period for cyclical pain, but a fairly consis-
tent effect over time in relation to dyspareunia.
Averaging across time points, there were significant dif-
ferences in favour of the electrodiathermy group in respect
of three subscales of the EHP-30: pain, emotional wellbeing
and self-image (Table 3).
Mean (SD) intraoperative blood loss was 24 ml (29 ml)
(range 0–200 ml) in the electrodiathermy group and 15 ml
(17 ml) (range 0–100 ml) in the helium group. Following a
natural-logarithm transformation of the data (owing to
violation of the assumptions of normality and homogeneity
of variance of the residuals), this difference was tested
through a Student’s t-test; the back-transformed data are
expressed as a fold change. Compared with the helium
group, blood loss in the electrodiathermy group was 1.43
times greater (95% CI 0.96, 2.15), but this effect was not
statistically significant (t = 1.757; P = 0.081). No visceral
complications were noted, nor any postoperative complica-
tions.
The operative duration was slightly longer in the electro-
diathermy group (mean 37.66 minutes, SD 12.56 minutes;
two missing values) than in the helium group (mean
36.02 minutes, SD 11.89 minutes; six missing values). This
difference of 1.64 minutes was not significant (t = 0.907;
P = 0.365). Among women who had tried to become preg-
nant following surgery (n = 81), 17/44 (38.6%; 11 missing
values) in the electrodiathermy and 9/37 (24.3%; 14 miss-
ing values) in the helium group had succeeded in doing so.
This difference was not significant (odds ratio with electro-
diathermy as reference category, 0.554, 95% CI 0.200,
1.481; P = 0.234). Given the maximum-likelihood estima-
tion, the 25 missing values in this analysis were not
imputed.
A secondary unadjusted analysis on the primary outcome
measure yielded a significant, but smaller, effect across all
time points (mean difference, 7.90 mm; 95% CI 0.60,
15.20; P = 0.034). The effect at 12 weeks was non-signifi-
cant (mean difference, 6.42 mm; 95% CI 2.93, 15.77;
P = 0.177).
Discussion
Main findings
In this randomised controlled trial comparing the effect of
the treatment of mild-to-moderate endometriosis with elec-
trodiathermy or helium thermal coagulator, a statistically
significant difference in cyclical pain scores was detected at
12 weeks in favour of electrodiathermy. Across all time
points there was also a statistically significant difference in
cyclical pain in favour of the electrodiathermy group. For
the secondary outcome measures, statistically significant
differences favoured electrodiathermy for dyspareunia atT
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12 weeks. The effects seen on cyclical pain and dyspareunia
were, however, both smaller than the proposed MID and
therefore cannot be assumed to be clinically important.
Small but statistically significant differences in some qual-
ity-of-life measures (pain, emotional wellbeing and self-im-
age) also favoured the use of electrodiathermy.
Strengths and limitations
This trial provides high-quality evidence comparing the use
of a helium thermal coagulator to electrodiathermy in the
treatment of mild-to-moderate endometriosis. Its design
was informed by the perspectives of patients, and their
views on outcome measures and timing of follow-up were
particularly helpful. The study was double-blinded, except
for the surgeon, who of necessity was not blind to the
intervention. Only one woman failed to receive the
assigned intervention. Analysis was performed on an
intention-to-treat basis and steps were put in place to min-
imise loss to follow up.
Over-recruitment to meet the desired sample size was
needed because of the larger than expected number of par-
ticipants being rejected in theatre prior to randomisation
(n = 106). This was either because of an absence of disease
or because the disease was classified as more severe than
mild to moderate, and suggests the need for a more effec-
tive way to determine which patients will benefit from
laparoscopic surgery.
Interpretation
Meta-analysis of laparoscopic treatment of endometriosis
has shown a superior reduction in symptoms compared
with diagnostic laparoscopy alone.7 Defining which laparo-
scopic technique yields the best results has been the focus
of much debate and research. In our trial, participants in
Table 3. Estimates of mean differences in secondary outcome variables at 12-week follow up and averaged across all follow-up time points
(differences are helium group minus electrodiathermy group)
12-week follow-up:
difference (95% CI); P value
All follow-up time points:
difference (95% CI); P value
VAS score for dyspareunia (mm) 11.66 (1.39, 21.93); 0.026 8.13 (0.08, 16.34); 0.052
EHP-30 pain 6.38 (0.88, 13.64); 0.085 6.32 (0.49, 12.15); 0.034
EHP-30 control and powerlessness 4.94 (3.68, 13.56); 0.259 5.47 (1.65, 12.58); 0.131
EHP-30 emotional wellbeing 6.47 (0.13, 13.08); 0.055 5.54 (0.00, 11.08); 0.050
EHP-30 social support 5.05 (3.59, 13.68); 0.250 5.60 (1.10, 12.31); 0.101
EHP-30 self-image 5.79 (2.33, 13.91); 0.161 7.16 (0.10, 14.22); 0.047
Values are derived from linear mixed models (including all randomised participants) adjusted for baseline value, age, surgeon, Revised American
Society of Reproductive Medicine classification and previous abdominal surgery.
EHP-30, Endometriosis Health Profile (each dimension scored 0–100; positive differences indicate better quality of life in the electrodiathermy
group). VAS, visual analogue scale (positive differences indicate less dyspareunia in the electrodiathermy group).
Figure 2. Profile plots for cyclical pain and dyspareunia (covariate-adjusted mean values).
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both treatment arms could receive ablation and/or excision,
according to clinical judgment. Other trials that have
specifically compared ablation with excision of endometrio-
sis have demonstrated comparable reductions in the sever-
ity of symptoms.12,21,22 Meta-analysis, however, has shown
a greater improvement in symptoms of endometriosis at
12 months with excision than with ablation.23
It has been suggested that the benefit of excision is the
removal of deep disease, conferring better symptomatic
relief than ablation, which may just treat superficial disease,
leaving deeper disease behind. We theorise that this is the
likely mechanism by which electrodiathermy showed statis-
tically superior results in this trial – albeit not of clinical
significance – as excision was much more commonly per-
formed with this technique than with the helium thermal
coagulator. As traditional electrodiathermy allows for the
excision of deeper endometriotic tissues, it may therefore
provide a greater degree of reduction in symptoms such as
pain and dyspareunia, which are considered to be associ-
ated with deeper disease.
In this study, helium coagulation was not shown to be
clinically superior to electrodiathermy in the laparoscopic
treatment of mild-to-moderate endometriosis. Surgeons
may therefore choose to base their choice of intervention
on other considerations. Faced with disease overlying deli-
cate structures, such as the bladder, bowel and diaphragm,
they may favour the use of helium coagulation, owing to
its low thermal spread. Conversely, a desire to achieve dee-
per excision may prompt them to use electrodiathermy.
The interventions performed in this study were under-
taken by surgeons working in an accredited endometriosis
centre and the results obtained may not reflect those
achieved by a general gynaecologist. For example, the exci-
sion performed through electrodiathermy may have been
fuller and deeper than that undertaken by a generalist.
Conclusion
In conclusion, although laparoscopic treatment of mild-to-
moderate endometriosis with electrodiathermy showed sta-
tistically significant superior improvement in symptoms of
cyclical pain, dyspareunia and some quality-of-life mea-
sures, when compared with treatment with a helium ther-
mal coagulator, the magnitude of these effects was
generally too small to infer that they are clinically impor-
tant. Further research, including health economics evalua-
tion, is needed before clear recommendations can be made
for clinical practice.
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